As one of the world’s most renowned companies for contract development and manufacturing, Lonza Pharma & Biotech is recognized for our reliable, high-quality services, our global capacity, our innovative technology platforms, and our extensive experience. From 2013 to 2016, our contributions supported 36% of launches with small-molecule breakthrough designation. In 2016 alone, we provided manufacturing services for more than 50 commercial molecules and conducted more than 250 development programs. We have helped launch pioneering autologous cell therapies.
Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.
We believe that the best outcome – for you and for your patients – can only come as a result of a successful collaboration. Together, we can solve the next challenge and bring your next medicine to life.
Lonza acquired Capsugel to create an integrated solutions provider to the global pharma and consumer healthcare industries.
Are you looking for a reliable, experienced, and adaptive partner with expertise in drug substance and drug product? We have the capacity to manage projects from pre-clinical stage to commercialization successfully. Let's meet the next challenge together.